Sympatient GmbH – Trademark Portfolio
Entity Type: 99
Sympatient GmbH holds 1 U.S. trademark filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 42 (Computer & Scientific) — 1 filings in this category. The portfolio also extends into Class 9 (Computers & Electronics) across 4 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include INVIRTO. The owner is based in Hamburg.
Friedensallee 7-9
Hamburg 22765 , DE
Showing of trademarks Trademarks
Trademark Classifications
Sympatient GmbH's trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific and technological services; industrial analysis and research services
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Education; providing of training; entertainment; sporting and cultural activities
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Frequently Asked Questions
How many trademarks does Sympatient GmbH have?
Sympatient GmbH has 1 U.S. trademark filed with the USPTO. Of these, 1 registered.
What trademark classes does Sympatient GmbH file in?
Sympatient GmbH files trademarks across 4 Nice Classification classes. The most active classes are Class 42 (Computer & Scientific), Class 9 (Computers & Electronics), Class 41 (Education & Entertainment), Class 44 (Medical Services). Class 42 covers scientific and technological services; industrial analysis and research services.
What are Sympatient GmbH's most well-known trademarks?
Sympatient GmbH's registered trademark portfolio includes well-known marks such as INVIRTO. These are among 1 currently registered trademark in the portfolio.
What is Sympatient GmbH's trademark registration success rate?
Sympatient GmbH has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 0 applications are pending review.